Pfizer is to build a new $35 million clinical research centre in an R&D 'hotspot' in New Haven, Connecticut.

Due to open in 2005, the centre will employ cutting edge imaging technology to monitor metabolisation of medicines in phase I clinical trials.

Some studies at the centre will be undertaken in collaboration with nearby Yale University School of Medicine, one of the world's leading centres for imaging technology.

Yale scientists will use positron emission topography (PET) and other scanning technology to track the metabolisation of drugs in volunteers.

Connecticut Governor John G Rowland welcomed the new investment, and said it contributed to a 139% increase in R&D spending in the region in just six years.

"Just as important, this collaboration between Pfizer and Yale University marks yet another milestone in Connecticut's efforts to be recognised worldwide as a 'hotspot' for bioscience companies".

In exchange for its investment, Pfizer will take ownership of the site from the State, and will also be eligible for property tax under an Enterprise Zone programme.

pharmafocus@pharmafile.co.uk